Ruxience
Pfizer scores EU approval for MabThera biosimilar Ruxience
April 6, 2020Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar
The European Commission has moved to authorise Ruxience, Pfizer’s biosimilar version of MabThera (rituximab). The decision marks the seventh biosimilar …
Europe’s CHMP recommends Pfizer’s biosimilar of Roche’s MabThera
February 4, 2020Manufacturing and Production, Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar, pharma
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has revealed that it has awarded a positive opinion for …
FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan
July 24, 2019Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma
Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
